Advances in treatment of brain glioma

doi:10.3877/cma.j.issn.2095-9141.2017.02.011

Abstract

Abstract:

Glioma is the most common primary intracranial tumor. Radical surgery combined with radiotherapy and chemotherapy are the basic treatment method of glioma, but because of its easy recurrence and high mortality, the treatment effects are not optimistic. With the continuous research and understanding of glioma in recent years, gene therapy, immunotherapy, molecular targeted therapy and other therapies are put forward. This study is aimed to summarize the current treatments in glioma.

Key words: Glioma, Gene therapy, Immunotherapy, Molecular targeted therapy

Shengpan Chen, Xiaokun Zuo, Ying Xia. Advances in treatment of brain glioma[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(02): 105-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2017.02.011

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2017/V03/I02/105

References 31

[1]	Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015, 17 suppl 4: iv1-iv62.
[2]	江涛.脑胶质瘤治疗技术与进展[M].北京:人民卫生出版社, 2011: 12.
[3]	《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中国医学杂志, 2016, 96(7): 485-509.
[4]	Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomized, controlled trial[J]. Lancet Oncol, 2011, 12(11): 997-1003.
[5]	Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts[J]. Neurosurgery, 2007, 61(5): 935-949.
[6]	Leroy HA, Vermandel M, Lejeune JP, et al. Fluorescence guided resection and glioblastoma in 2015: a review[J]. Lasers Surg Med, 2015, 47(5): 441-451.
[7]	刘明，刘楠，刘晓亮,等.荧光素钠引导辅助下胶质瘤切除的应用[J].中国实验诊断学, 2015, (2): 210-213.
[8]	Su X, Huang QF, Chen HL, et al. Fluorescence-guided resection of high-grade gliomas: a systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2014, 11(4): 451-458.
[9]	戴宜武，王振光，秦家振.脑胶质瘤研究进展[J].脑胶质瘤治疗进展, 2013, 14(7): 6225-6228.
[10]	杨文涛，于喜贞，李正友,等.胶质瘤综合治疗方法研究进展[J].新乡医学院学报, 2016, 33(1): 70-77.
[11]	李博，莫志海，李钰,等. 96例脑胶质瘤术后放射治疗预后影响因素分析[J].临床军医杂志, 2015, 43(5): 487-489, 492.
[12]	杨森，董立新，付占昭,等.恶性胶质瘤术后三维适形放射治疗的临床疗效及不良反应[J].医学信息, 2015, 28(11): 312-313.
[13]	陈宝师，张伟，张忠,等.成人弥漫性低级别胶质瘤替莫唑胺化疗的临床研究[J].中国肿瘤临床, 2016, 43(17): 753-756.
[14]	Stupp R, Mason WP, van den Bent MJ, et al. Radiotheraphy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
[15]	Arvold ND, Cefalu M, Wang Y, et al. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma[J]. J Neurooncol, 2016, Epub ahead of print.
[16]	Zhang CX, Zhao WY, Liu L, et al. A nanostructure of functional targeting epirubicin liposomes modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment[J]. Oncotarget, 2015, 6(32): 32681-32700.
[17]	Capdevila L, Cros S, Ramirez JL, et al. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation[J]. J Neurooncol, 2014, 117(1): 77-84.
[18]	张倩，曹蓓.胶质瘤的免疫治疗研究进展[J].中华神经医学杂志, 2016, 15(8): 856-859.
[19]	Brower V. Checkpoint blockade immunotherapy for cancer comes of age[J]. J Natl Cancer Inst, 2015, 107(3). pii: djv069.
[20]	Tivnan A, Heilinger T, Lavelle EC, et al. Advances in immunotherapy for the treatment of glioblastoma[J]. J Neurooncol, 2016, Epub ahead of print.
[21]	Wang X, Zhao HY, Zhang FC, et al. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review[J]. Cancer Invest, 2014, 32(9): 451-457.
[22]	Polyzoidis S, Tuazon J, Brazil L, et al. Active dendritic cell immunotherapy for glioblastoma: current status and challenges[J]. Br J Neurosurg, 2015, 29(2): 197-205.
[23]	郑丽影，吕红，林赋桂,等.脑胶质瘤治疗策略及其研究进展[J].吉林医药学院学报, 2016, 37(1): 50-53.
[24]	王浩，潘建青，胡继良,等.腺病毒介导的HSV-TK/GCV在Cfos启动子调控下对胶质瘤细胞的杀伤作用[J].中华神经医学杂志, 2015, 14(6): 558-562.
[25]	Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400.
[26]	Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma[J]. N Engl J Med, 2014,370(8): 699-708.
[27]	Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly disgnosed glioblastoma[J]. N Engl J Med, 2014, 370(8): 709-722.
[28]	费帆，何永生.脑胶质瘤分子靶向与优化治疗[J].实用医院临床杂志, 2011, 8(2): 199-201.
[29]	Wang Y, Pan L, Sheng XF, et al. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in chinese patients[J]. Asia Pac J Clin Oncol, 2014, 12(1): e23-e29.
[30]	Mittal S, Pradhan S, Srivastava T. Recent advances in targeted therapy for glioblastoma[J]. Expert Rev Neurother, 2015, 15(8): 935-946.
[31]	王岩.三芪抗瘤汤治疗脑胶质瘤术后60例临床观察[J].河北中医药学报, 2007, 22(2): 19-20, 22.

Please choose a citation manager

Content to export